In the rapidly evolving landscape of genomic medicine, messenger RNA (mRNA) has emerged as a cornerstone for delivering gene editing tools. Unlike DNA-based delivery methods, mRNA offers a transient, non-integrating, and highly efficient approach to expressing site-specific nucleases and editors. At CD BioGlyco, we provide a specialized gene editing mRNA synthesis service designed to support researchers in navigating the complexities of modern genome engineering. We produce high-purity mRNA encoding a variety of editing enzymes, from classical gene editing-associated proteins to sophisticated base and prime editors.
Our service is meticulously integrated into our therapeutic nucleic acid development platform, ensuring that every transcript is optimized for stability, translation efficiency, and reduced immunogenicity. Whether your goal is to knock out a disease-causing gene, correct a point mutation, or engineer complex cellular traits, CD BioGlyco delivers the high-quality genetic material required to achieve consistent and reproducible results in both in vitro and in vivo systems.
We utilize high-fidelity T7 RNA polymerases and optimized buffer systems to minimize the production of double-stranded RNA (dsRNA) by-products. This reduces the activation of innate immune sensors, ensuring that the gene editing mRNA remains functional within target cells.
We employ both enzymatic and co-transcriptional capping strategies to ensure a natural Cap-1 structure. Coupled with precise poly(A) tail length control, our transcripts exhibit enhanced half-lives and protein expression levels.
We offer comprehensive chemical modifications, such as the incorporation of N1-methylpseudouridine (m1ψ) or 5-methoxyuridine (5moU), which have been proven to significantly enhance the safety profile of therapeutic mRNA.
As a specialized component of our therapeutic oligonucleotide synthesis service, CD BioGlyco provides a comprehensive range of mRNA synthesis options tailored specifically for gene editing applications. Our scope includes:
We begin by analyzing the target enzyme sequence. Utilizing proprietary algorithms, we optimize codons and secondary structures to enhance translational efficiency and avoid premature degradation, ensuring the mRNA performs optimally in your target organism.
High-purity plasmid DNA (pDNA) templates are synthesized or prepared. The pDNA is then precisely linearized using restriction enzymes to provide a clear termination point for the IVT process, ensuring the production of uniform, full-length transcripts.
The linearized template undergoes transcription in a controlled environment. We monitor the reaction parameters closely to maximize yield while maintaining the integrity of the nascent mRNA molecules and minimizing truncated fragments.
Following transcription, the mRNA undergoes capping and polyadenylation. This step is critical for protecting the mRNA from exonucleases and ensuring it is recognized by the cell's ribosomal complex for immediate protein synthesis.
We use advanced purification techniques, including high-performance liquid chromatography (HPLC) and tangential flow filtration (TFF), to remove residual DNA, enzymes, and immunogenic dsRNA, resulting in a highly pure final product.
Every batch undergoes rigorous QC testing, including fragment analysis for integrity, sequence verification, endotoxin testing, and purity assessment via capillary electrophoresis (CE), ensuring the mRNA meets the highest research standards.
DoI: 10.3390/molecules29194713
Journal: Molecules
IF: 4.6
Published: 2024
Results: This article focuses on optimizing in vitro mRNA synthesis via T7 RNA polymerase (T7 RNAP) to reduce impurities, especially immunogenic dsRNA. The authors found that the G753A mutation in T7 RNAP's specificity loop cuts dsRNA production to 17.76±1.37% by weakening non-specific binding and lowering antisense RNA levels, without reducing mRNA yield. Combining G753A with modified nucleotide m1ψTP further drops dsRNA to <3%. Though G753A increases fragmented mRNA, adding the K389A mutation (known for high mRNA integrity) restores mRNA integrity to wild-type levels while maintaining low dsRNA. This cost-effective strategy of engineered T7 RNAP (G753A+K389A) with m1ψTP enables high-purity, low-immunogenicity mRNA synthesis, aiding mRNA therapeutic development.
Fig.1 T7 RNAP-transcribed RNA synthesis. (He, et al., 2024)
Therapeutic Development
Gene editing mRNA is a vital tool for developing treatments for rare genetic disorders and oncology. It enables the precise correction of mutations or the engineering of immune cells for advanced adoptive cell therapies.
Functional Genomics
Researchers use our high-purity mRNA to perform high-throughput gene knockout or knock-in studies. This facilitates the rapid identification of gene functions and the discovery of novel drug targets in various disease models.
Agricultural Biotechnology
In plant and animal sciences, mRNA-delivered editors allow for the development of climate-resilient crops and improved livestock traits. This approach bypasses the long-term presence of foreign DNA.
In Vitro Disease Modeling
Our synthesis service supports the creation of precise cellular models of human diseases. By editing induced pluripotent stem cells (iPSCs), scientists study disease progression and test potential therapeutic interventions in a relevant genomic context.
Exceptional Purity Levels
CD BioGlyco utilizes specialized purification workflows to virtually eliminate dsRNA and other contaminants. This results in mRNA with significantly reduced immunogenicity and higher protein expression efficiency in sensitive primary cell types.
Customizable Modification Profiles
We offer a wide array of modified nucleosides to tailor the mRNA's stability and immune profile. This customization ensures that the gene editing tools are optimized for your specific experimental needs.
Scalable Production Capabilities
Whether you require microgram quantities for pilot studies or gram-scale amounts for preclinical trials, our platform scales seamlessly. We maintain stringent quality standards across all production volumes to ensure reliable results.
Expert Sequence Engineering
Our team possesses deep expertise in UTR design and codon optimization. We provide scientific insights that help maximize the half-life and translational yield of your gene editing enzymes in diverse biological systems.
"The Cas9 mRNA provided by CD BioGlyco exceeded our expectations in terms of both purity and performance. We observed significantly lower toxicity in our primary human T-cell cultures compared to other sources, allowing us to achieve high editing efficiencies without compromising cell viability."
– J.R., Senior Scientist
"We switched to CD BioGlyco for our base editor mRNA synthesis, and the results have been remarkably consistent. The high capping efficiency and low dsRNA content have made a noticeable difference in our in vivo studies."
– A.D., Director of Molecular Biology
"Working with the team at CD BioGlyco has been a seamless experience. Their expertise in the therapeutic nucleic acid development platform is evident in the quality of the transcripts they produce. The detailed QC reports gave us the confidence we needed to move forward with our complex multiplexed editing projects."
– B.G., Principal Investigator
CD BioGlyco is committed to providing world-class gene editing mRNA synthesis services that empower researchers to push the boundaries of what is possible in genome engineering. By combining advanced IVT technologies with rigorous purification and expert sequence design, we ensure that your gene editing tools are delivered with the highest levels of activity and safety. Please feel free to contact us to discuss your specific requirements and help you design the optimal synthesis strategy.
Reference
